David T. Dunn

David T. Dunn

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 138 publications

Sample size estimation for the averted events ratio.

Sample size estimation for the averted events ratio.

Journal: Clinical trials (London, England)

Published: October 23, 2025

A Comparison of F/TAF and F/TDF as HIV Pre-Exposure Prophylaxis in a Predominantly Cisgender Women Population in East and South Africa: A Randomized, Factorial, Noninferiority Trial.

A Comparison of F/TAF and F/TDF as HIV Pre-Exposure Prophylaxis in a Predominantly Cisgender Women Population in East and South Africa: A Randomized, Factorial, Noninferiority Trial.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: September 01, 2025

Prevalence and factors associated with use of prophylaxis for HIV and sexually transmitted infections among sexual health service attendees in England: findings from a cross-sectional observational study.

Prevalence and factors associated with use of prophylaxis for HIV and sexually transmitted infections among sexual health service attendees in England: findings from a cross-sectional observational study.

Journal: BMJ public health

Published: August 05, 2025

Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm.

Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm.

Journal: HIV research & clinical practice

Published: June 11, 2025

Evidence for circulation of high-virulence HIV-1 subtype B variants in the United Kingdom.

Evidence for circulation of high-virulence HIV-1 subtype B variants in the United Kingdom.

Journal: Virus evolution

Published: January 29, 2025

Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trial.

Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trial.

Journal: Clinical trials (London, England)

Published: January 23, 2025

Exploring different objectives in non-inferiority trials.

Exploring different objectives in non-inferiority trials.

Journal: BMJ (Clinical research ed.)

Published: June 17, 2024

MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV.

MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV.

Journal: AIDS (London, England)

Published: May 31, 2024

Assessing Whether Providing Regular, Free HIV Self-Testing Kits Reduces the Time to HIV Diagnosis: An Internet-Based, Randomized Controlled Trial in Men Who Have Sex With Men.

Assessing Whether Providing Regular, Free HIV Self-Testing Kits Reduces the Time to HIV Diagnosis: An Internet-Based, Randomized Controlled Trial in Men Who Have Sex With Men.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: May 28, 2024

Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV.

Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV.

Journal: AIDS (London, England)

Published: December 07, 2023

Needs & networks: understanding the role and impact of social networks on HIV (self-)testing among GBMSM and trans people in England and Wales.

Needs & networks: understanding the role and impact of social networks on HIV (self-)testing among GBMSM and trans people in England and Wales.

Journal: BMC public health

Published: October 12, 2023

Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).

Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).

Journal: EClinicalMedicine

Published: August 01, 2023

Showing 1-12 of 138

Last Updated: 09/26/2026